Bladder Cancer Clinical Trial in Atlanta GA
Have you or your loved ones been diagnosed with bladder cancer?
You may be eligible to participate in a bladder cancer clinical trial.
Have you or your loved ones been diagnosed with bladder cancer? You may be eligible to participate in a bladder cancer clinical trial.
Where you'll go
Details for the study
Treatments and/or Procedures
Inclusion Criteria: - Pathologic diagnosis of urothelial or squamous cell carcinoma of the bladder - Patients must have undergone cystectomy (total cystectomy, radical cystectomy +/- pelvic lymph node dissection) with no evidence of macroscopic residual disease - Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0-2 - Patients treated with simple cystectomy with macroscopically negative margins are eligible for this study - Clinical T-stage (prior to systemic therapy, if applicable) ≥ T3a and/or positive lymph nodes by transurethral resection of bladder tumor (TURBT)/magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET)-CT or pathologic T-stage ≥ T3a and/or positive lymph nodes Exclusion Criteria: - Patients with metastatic disease outside of the pelvis - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years - Prior radiation therapy to the pelvis - Patients with active inflammatory bowel disease - Severe acute co-morbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization in the last 3 months - Transmural myocardial infarction within the last 6 months - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration - Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatment involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immunocompromised patients
Interested in participating?
Emory University Hospital Winship Cancer Institute
1365 Clifton Road, Atlanta, GA, USA 30322